Skip to main content
Premium Trial:

Request an Annual Quote

Laura Clague

Laura Clague has been appointed to the board of directors of Fluidigm. She is the CFO of Retrophin. Previously, she was the CFO of the San Diego and Ohio operations of Amylin Pharmaceuticals, following the company's acquisition by Bristol-Myers Squibb. Prior to that, she was vice president, corporate controller, and principal accounting officer at Amylin, as well as CFO of Amylin's collaboration with Eli Lilly and Company. Clague holds a BS in business administration from Menlo College.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more